"Because no one knew in 2013 all Brilacidin could do."
It's hard for me to believe that others would have bid on brilacidin and the other PYMX IP if they knew that it still wouldn't have generated a marketable drug 10 years later. To the contrary, it's more likely that a concern about that very outcome kept them away.
As you noted I asked this:
"If brilacidin was such a great investment, why didn't anyone else other than Eagle Eye Ehrlich throw money into it?"
No reasonable person would define a great investment as one that generated a loss in share price of 99% in a decade (as this one did).
Your examples didn't do that, did they? And why are you comparing companies with revenues to one that doesn't have any?
"Sentimentality about an asset leads to a lack of discipline."
“I have had a wonderful time but this wasn't it.”
..........Groucho